INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
INO$1.51+24.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| For the Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue from collaborative arrangements and other contracts, including affiliated entity | $217,756 | $832,010 |
| Operating expenses: | ||
| Research and development | 75,620,340 | 86,676,563 |
| General and administrative | 36,996,338 | 47,582,104 |
| Impairment of goodwill | — | 10,513,371 |
| Total operating expenses | 112,616,678 | 144,772,038 |
| Loss from operations | (112,398,922) | (143,940,028) |
| Other income (expense): | ||
| Interest income | 4,766,993 | 8,133,290 |
| Interest expense | (177,833) | (1,222,789) |
| Change in fair value of common stock warrant liability | 2,808,608 | — |
| (Loss) gain on investment in affiliated entity | (1,166,443) | 773,145 |
| Net unrealized gain on available-for-sale equity securities | 2,077,182 | 5,850,626 |
| Other expense, net | (3,163,711) | (4,711,596) |
| Net loss | $(107,254,126) | $(135,117,352) |
| Net loss per share | ||
| Basic and diluted | $(3.95) | $(6.09) |
| Weighted average number of common shares outstanding | ||
| Basic and diluted | 27,160,863 | 22,173,662 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.